hTERT MODULATORS AND METHODS OF USE
AssigneeArizona Board of Regents on Behalf of the University of Arzona
InventorsLaurence HURLEY, Vijay GOKHALE, HyunJin KANG, Kui WU
Life of this patent
Estimating the term…
Abstract
The present invention provides hTERT modulators and methods for producing and using the same. In particular, the present invention provide a compound of the formula as described herein. Some aspects of the invention are based on the characterization of the effect of hTERT core promoter region mutants on the 5-12 G-quadruplex structure and its stability. It is believed that some of the compounds of the invention bind selectively to the G-quadruplex in the hTERT core promoter mutant, which results in reversal of the effect of mutant promoter activation.
Claims13
A compound of the formula:
- wherein
- X is O or N such that when X is O, bond a is absent and when X is N, bond a is present;
- n is 0 or 1 such that:when n=0, R3 is —NHC(═NH)NH2;
- andwhen n=1, R3 is hydrogen, alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl or optionally substituted aryl, wherein each substituent is independently selected from the group consisting of halogen, cyano, nitro, azido, haloalkyl, cycloalkyl, heteroaryl, aryl, —NR7R8, —NR7C(O)R8, —C(O)NR7R8, —C(O)R9, —C(O)OR9, —S(O)R9, —SO2R9, —SO2NR7R8, —OR9 and —SR9;
- R1 is optionally substituted aryl or optionally substituted heteroaryl, wherein each substituent is independently selected from the group consisting of halogen, cyano, nitro, azido, haloalkyl, cycloalkyl, —NR4R5, —NR4C(O)R5, —C(O)NR4R5, —C(O)R6,—C(O)OR6, —S(O)R6, —SO2R6, —SO2NR4R5, —OR6, and —SR6;
- R2 is selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl and cycloalkyl;
- each of R4 and R5 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroaryl, aryl and cycloalkyl, or R4 and R5 together with the nitrogen atom to which they are attached to form an optionally substituted monocyclic or bicyclic ring with one or more heteroatoms;
- R6 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteraryl, aryl, cycloalkyl, wherein the alkyl, alkenyl, heteraryl, aryl and cycloalkyl are optionally substituted with one or more halo, cyano, alkylamino, alkoxy, aryl, heteroaryl or heterocyclyl groups;
- each of R7 and R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroaryl, aryl and cycloalkyl, or R7 and R8 together with the nitrogen group to which they are attached to form an optionally substituted monocyclic or bicyclic ring with one or more heteroatoms;
- R9 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteraryl, aryl cycloalkyl, wherein the alkyl, alkenyl, heteraryl, aryl and cycloalkyl are optionally substituted with one or more halo, cyano, alkylamino, alkoxy, aryl, heteroaryl or heterocyclyl groups;
- eachR11 and R12 is independently —H, —COR13 or —CH3;
- and
- R13 is alkyl, haloalkyl, alkenyl, alkynyl, or cycloalkyl
A compound of table 1 or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
Dependencies are inferred from the claim text.